Elicio Therapeutics, Inc. Revenue from Contract with Customer, Including Assessed Tax
Elicio Therapeutics, Inc. (ELTX) reported Revenue from Contract with Customer, Including Assessed Tax of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2023-05-10
- Elicio Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2022-06-30 was $653.00K, a 20.93% increase year-over-year.
- Elicio Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $2.30M, a 91.63% decline from fiscal 2021.
- Elicio Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2021 was $27.51M, a 14151.81% increase from fiscal 2020.
- Elicio Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2020 was $193.00K.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-05-10 | $0.00 derived: sum of 3 quarters · filed 2023-05-10 | $653.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $0.00 derived: sum of 2 quarters · filed 2023-03-17 | $653.00K derived: sum of 3 quarters · filed 2023-03-17 | $2.30M 10-K · filed 2023-03-17 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | $653.00K derived: sum of 2 quarters · filed 2022-11-14 | $2.30M 10-Q · filed 2022-11-14 | $27.44M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-06-30 | $653.00K 10-Q · filed 2022-08-15 | $2.30M 10-Q · filed 2022-08-15 | $27.44M derived: sum of 3 quarters · filed 2023-05-10 | $28.90M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-03-31 | $1.65M 10-Q · filed 2023-05-10 | $26.78M derived: sum of 2 quarters · filed 2023-05-10 | $28.24M derived: sum of 3 quarters · filed 2023-05-10 | $28.78M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $25.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $26.59M derived: sum of 2 quarters · filed 2023-03-17 | $27.14M derived: sum of 3 quarters · filed 2023-03-17 | $27.51M 10-K · filed 2023-03-17 |
| 2021-09-30 | $1.46M 10-Q · filed 2022-11-14 | $2.00M derived: sum of 2 quarters · filed 2022-11-14 | $2.37M 10-Q · filed 2022-11-14 | $2.56M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $540.00K 10-Q · filed 2022-08-15 | $911.00K 10-Q · filed 2022-08-15 | $1.10M derived: sum of 3 quarters · filed 2022-08-15 | $1.10M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $371.00K 10-Q · filed 2022-05-16 | $564.00K derived: sum of 2 quarters · filed 2022-05-16 | $564.00K derived: sum of 3 quarters · filed 2022-05-16 | $564.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $193.00K derived: sum of 2 quarters · filed 2022-03-30 | $193.00K derived: sum of 3 quarters · filed 2022-03-30 | $193.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |